Research and development in central nervous system diseases, diagnostics and medical devices
First written in FY2016. 14 of 26 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-11-09.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「In the medical devices field, the company is primarily advancing R&D on products in the surgical field. On 30 June 2025, it filed an application for marketing authorization for a dedicated medical device kit for Vyjuvek gel, a regenerative medicine product used to treat dystrophic epidermolysis bullosa, developed by Krystal Biotech Japan株式会社 (head office: Minato-ku, Tokyo), and obtained marketing authorization on 15 October of the same year. In addition, as a new product in its core surgical suture portfolio, the company obtained marketing authorization on 11 March 2026 for barbed sutures as a partial change to the approval for Monodiox.」
In the medical devices and surgical fields, the company obtained marketing authorization for a dedicated kit for a regenerative medicine product and approval for a partial change covering barbed sutures. - 2026-04-01AdvancedOther Disclosures
「The new building’s operation will strengthen the production system for small-molecule pharmaceuticals and enable full-scale entry into contract manufacturing of highly potent drug products and contract inspection, packaging and testing of sterile drug products.」
A new pharmaceutical manufacturing building at the Gunma Plant began operating, expanding small-molecule production capacity and advancing contract manufacturing of highly potent drug products and contract services for sterile drug products. Commercial production is targeted after PQ and PV. - FY2026-H1AdvancedAnnual report
「In September 2025, consolidated subsidiary アルフレッサ ファーマ株式会社, headquartered in Chuo-ku, Osaka, obtained manufacturing and marketing approval in Japan for Neffy® nasal spray 1 mg/2 mg, an adjunctive treatment for anaphylaxis. Its generic name is adrenaline.」
The adjunctive treatment for anaphylaxis progressed from the marketing authorization application stage in the previous fiscal year to obtaining marketing authorization in Japan in September 2025. - FY2025AdvancedAnnual report
「The company filed an application for marketing authorization in November 2024.」
The company entered into a development and sales license agreement in Japan for an adrenaline nasal solution as an adjunctive treatment for anaphylaxis, progressing to the marketing authorization application stage. - FY2024AdvancedAnnual report
「In the diagnostics field, the company is advancing development of rapid diagnostic kits, primarily for respiratory infections, including point-of-care testing (POCT), as well as fecal occult blood testing reagent systems for use in colorectal cancer screening and other products in the gastrointestinal disease field. In September 2023, the company obtained partial approval for a change to the marketing authorization of a testing reagent used to assist in assessing ulcerative colitis, adding indications for the diagnosis of inflammatory bowel disease and assistance in assessing Crohn's disease. The product became covered by public health insurance in January 2024.」
The company obtained partial approval for a change to the marketing authorization adding indications for a diagnostic reagent, which became covered by public health insurance in January 2024. In medical devices, it also began selling a pump for a new Parkinson's disease treatment, marking progress toward commercializing R&D products. - FY2023AdvancedAnnual report
「Development of a treatment for amyotrophic lateral sclerosis, a designated intractable disease, began in March 2023.」
In R&D for central nervous system diseases, domestic development of an ALS treatment began under an agreement with K Pharma,Inc. The company also disclosed the launch of a fecal occult blood testing reagent and the acquisition of marketing authorization for a medical device. - FY2023-Q1RestatedAnnual report
「There were no material changes in the status of the Group’s research and development activities during the three-month period ended March 31, 20XX.」
The company reconfirmed that there were no material changes in R&D activities. R&D expenses were ¥391 million, up 10.2% year on year. - FY2022-Q2RestatedAnnual report
「There were no material changes in the status of the Group's R&D activities during the cumulative second quarter under review.」
The company states that there were no material changes in R&D activities. R&D expenses were ¥691 million, up 4.9% year on year. - FY2022-Q1RestatedAnnual report
「There were no material changes in the status of the Group’s research and development activities during the three-month period ended March 31, 20XX.」
The company states that there were no material changes in R&D activities. R&D expenses were ¥355 million, up 10.5% year on year. - FY2021AdvancedAnnual report
「In March 2021, the company obtained marketing authorization for the new COVID-19 (SARS-CoV-2) antigen rapid test kit Alsonic® COVID-19 Ag, which provides a result within 5 minutes of applying the sample.」
The COVID-19 antigen rapid test kit obtained marketing authorization and progressed to the product provision stage, with results available in 5 minutes. - FY2021-Q3AdvancedAnnual report
「In October 2020, アルフレッサ entered into an agreement with its investee, Lily MedTech, Inc. (head office: Bunkyo-ku, Tokyo), granting it exclusive distribution rights in Japan to the company's breast ultrasound imaging diagnostic device for medical institutions.」
The company entered into an exclusive distribution agreement in Japan for Lily MedTech's breast ultrasound imaging diagnostic device, moving from R&D to commercial rollout. - FY2021-Q2RestatedAnnual report
「There were no material changes in the status of the Group's R&D activities during the cumulative second quarter under review.」
The company states that there were no material changes in R&D activities and disclosed R&D expenses of ¥659 million, down 6.8% year on year. - FY2021-Q1RestatedAnnual report
「There were no material changes in the status of the Group’s research and development activities during the three-month period ended March 31, 20XX.」
The company states that there were no material changes in R&D activities and disclosed R&D expenses of ¥321 million, down 15.5% year on year. - FY2020-Q3RestatedAnnual report
「In September 2019, アルフレッサ invested in Lily MedTech, Inc. (head office: Bunkyo-ku, Tokyo), a venture company developing a breast ultrasound imaging diagnostic device. The device developed by the company is expected to be a medical device that addresses current challenges in breast cancer screening.」
The investment in Lily MedTech, which is developing a breast ultrasound imaging diagnostic device, continues to be cited as an initiative in the R&D and medical devices fields, following the previous quarter. - FY2020-Q2AdvancedAnnual report
「In addition, in September of this year, アルフレッサ invested in Lily MedTech Co., Ltd. (head office: Bunkyo-ku, Tokyo), a venture company seeking to develop breast ultrasound imaging and diagnostic equipment. The equipment being developed by the company is expected to serve as a medical device addressing current challenges in breast cancer screening.」
In the medical devices field, the company invested in a venture company developing a breast ultrasound imaging diagnostic device. - FY2020-Q1AdvancedAnnual report
「In addition, on 27 June of this year, the company launched Neskeep®, an absorbable tissue spacer for radiation therapy, as a new product.」
The development product for particle-beam radiation therapy progressed to the new-product launch stage. - FY2019AdvancedAnnual report
「The company advanced development of the world's first absorbable implantable spacer for particle-beam cancer treatment, filed an application for marketing authorization in December 2017 and obtained approval in December 2018.」
The development product progressed from the marketing authorization application stage to approval in December 2018. - FY2019-Q3RestatedAnnual report
「There were no material changes in the status of the Group’s research and development activities during the nine-month period ended December 31, 20XX.」
The company states that there were no material changes in R&D activities. R&D expenses were ¥896 million, up 2.9% year on year. - FY2019-Q2RestatedAnnual report
「There were no material changes in the status of the group's R&D activities during the first half of the current consolidated cumulative period.」
The company states that there were no material changes in R&D activities. R&D expenses were ¥591 million, up 1.4% year on year. - FY2018-Q3RestatedAnnual report
「In June 2017, アルフレッサ ファーマ株式会社 (head office: Chuo-ku, Osaka Prefecture) launched the companion diagnostic OncoGuide® AmoyDx® ROS1 Fusion Gene Detection Kit.」
The companion diagnostic launched in the previous quarter continues to be cited as an achievement in product development and provision in the manufacturing business. - FY2018-Q2RestatedAnnual report
「In June 2017, アルフレッサ ファーマ株式会社 launched the companion diagnostic OncoGuide® AmoyDx® ROS1 Fusion Gene Detection Kit.」
The companion diagnostic launched in the previous quarter continues to be cited in the explanation of key initiatives in the manufacturing business. - FY2018-Q1AdvancedAnnual report
「In June 2017, アルフレッサ ファーマ株式会社 (head office: Chuo-ku, Osaka) launched the companion diagnostic “OncoGuide®AmoyDx®ROS1融合遺伝子検出キット.”」
A new companion diagnostic was launched in June 2017, marking concrete progress in product development and provision in the diagnostics field. - FY2017-Q1AdvancedAnnual report
「アルフレッサ ファーマ株式会社 (head office: Chuo-ku, Osaka) obtained marketing authorization for the antiepileptic drug Sabril® 500 mg powder in packets, jointly developed with サノフィ株式会社, and launched it in July of this year.」
Marketing authorization was obtained for the jointly developed product, which was launched in July 2016. - FY2016First statedAnnual report
「The group is strengthening and developing its product development management and evaluation systems, focusing its in-house development on selected fields, while also actively pursuing development through in-licensing from other companies and joint development with other companies.」
R&D expenses were ¥1,123 million. Development is focused on central nervous system diseases, rapid diagnostic kits and medical devices in the surgical field, alongside in-licensed and jointly developed products.